Azafaros
Last verified 2026-05-18. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $142.6Mattributed |
|---|---|
| Latest round | series-b, $142.6M, 2025-05-01attributed |
| Founded | 2018 |
| Headquarters | Leiden, Netherlands |
| Industry | bio |
| Stage | series-b+ |
| Website | azafaros.com |
Clinical-stage biotech advancing nizubaglustat, an oral azasugar for lysosomal storage disorders affecting the brain. Targets patients with GM1 and GM2 gangliosidoses and Niemann-Pick disease type C. Brain-penetrant chemistry from Leiden and Amsterdam UMC research is heading into two Phase 3 trials with a 132 million euro Series B.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-05-01 | series-b | $142.6M | undisclosed |
Detected tech stack
LiteSpeed, Afterpay, Google Tag Manager, PHP, jquery 1.9.1
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $142.6M | attributed | sifted named as publisher. No document URL on file. |
| Total raised $142.6M | attributed | sifted named as publisher. No document URL on file. |
| Company existence | self-reported | azafaros.com, read 2026-05-18 |
| Description | self-reported | azafaros.com, read 2026-05-18 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.